SEOM clinical guideline for the management of cutaneous melanoma (2020)

• M. Majem ^[1] ; J. L. Manzano ^[7] ; I. Marquez-Rodas ^[2] ; K. Mujika ^[8] ; E. Muñoz-Couselo ^[9] ; E. Pérez-Ruiz ^[3] ; L. de la Cruz-Merino ^[4] ; E. Espinosa ^[5] ; M. Gonzalez-Cao ^[10] ; A. Berrocal ^[6]
  1. [1] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  2. [2] Instituto de Investigación Sanitaria Gregorio Marañón

     Instituto de Investigación Sanitaria Gregorio Marañón

     Madrid, España

     
  3. [3] Hospital Costa Del Sol

     Hospital Costa Del Sol

     Marbella, España

     
  4. [4] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  5. [5] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  6. [6] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  7. [7] Hospital Germans Trias i Pujol
  8. [8] OSI Donostialdea-Onkologikoa
  9. [9] Vall d’Hebron Instituto de Oncología
  10. [10] Hospital Dexeus, Barcelona

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 5 (May), 2021 (Ejemplar dedicado a: SEOM clinical guidelines 2020), págs. 948-960
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.